Skip to search formSkip to main contentSkip to account menu

ETC-1002

National Institutes of Health

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2015
2015
Abstract 14653: Prevention of Diet-induced Metabolic Dysregulation, Inflammation and Atherosclerosis in Ldlr-/- Mice by Treatment With the ACL Inhibitor ETC-1002
ETC-1002 (8-hydroxy-2,2,14,14-tetramethylpentadecanedioic acid) is a novel LDL cholesterol-lowering compound. Preclinical studies… 
2014
2014
ETC-1002 Lowers LDL-Cholesterol and is Well Tolerated in Hypercholesterolemic Patients with Statin Intolerance†
2014
2014
ETC-1002 Reduces Blood Pressure in Hypercholesterolemic Patients with Mildly Elevated Blood Pressure
2013
2013
ETC-1002, A MODULATOR OF ADENOSINE MONOPHOSPHATE-ACTIVATED PROTEIN KINASE AND ADENOSINE TRIPHOSPHATE-CITRATE LYASE, WAS SAFE AND REDUCED LOW-DENSITY LIPOPROTEIN-CHOLESTEROL IN HEALTHY VOLUNTEERS
2013
2013
Abstract 62: The Effect of ETC-1002 on Low Density Lipoprotein-Cholesterol and Additional Risk Factors in Patients With Type 2 Diabetes
Patients with type 2 diabetes (T2DM) are at high risk for cardiovascular (CV) disease and over half do not achieve LDL-C goal… 
2013
2013
ETC-1002 Rapidly and Significantly Reduces LDL-Cholesterol and is Well Tolerated in Healthy Subjects†
2012
2012
Abstract 465: ETC-1002, a Novel Dicarboxylic Fatty Acid Analog, Inhibits Inflammatory Response in Primary Human Monocyte-Derived Macrophages as Well as in Adipose Tissue of Insulin-Resistant Mice via…
ETC-1002, a small molecule regulator of imbalances in lipid and carbohydrate metabolism, is an investigational drug currently in… 
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)